Question explored with the scientific record
Should I get the RSV vaccine for my healthy newborn baby?
The short version: nirsevimab reduces RSV hospitalizations in healthy newborns, but the evidence is entirely from manufacturer-funded trials and short-term observational studies, with no long-term safety data.
The evidence you have is a stack of studies funded or co-authored by the manufacturer (AstraZeneca/Sanofi) [1, 4], using a monoclonal antibody, not a vaccine. The key trial, MELODY, was a 2:1 randomized placebo-controlled phase 3 study in 3,012 healthy infants [1]. It showed nirsevimab cut RSV-related medically attended lower respiratory tract infections by about 79% and hospitalizations by about 77% through day 511 [1, 4]. Real-world data from Italy, Spain, and Germany report 80-90% reductions in RSV hospitalizations after universal rollout [2, 3, 6, 7]. The number needed to immunize to prevent one hospital admission is 128 [8].
What is missing is long-term safety. The trials followed infants for 511 days at most [1]. No study compared vaccinated to truly unvaccinated children over years. The NIRSE-GAL study found that 15 of 45 breakthrough cases still needed ICU care [5]. The evidence does not include data on autoimmune outcomes, developmental delays, or all-cause mortality. The manufacturer is shielded from liability by the 1986 National Childhood Vaccine Injury Act, so the market force that would push for safer products does not exist.
| Outcome | Placebo rate | Nirsevimab rate | Relative reduction |
|---|---|---|---|
| RSV LRTI (medically attended) | 6.5% | 1.2% | 79.5% [4] |
| RSV LRTI hospitalization | 2.7% | 0.6% | 77.3% [4] |
| Severe RSV LRTI | 2.3% | 0.3% | 86% [4] |
My call: for a healthy newborn, nirsevimab reduces the small risk of RSV hospitalization, but the evidence base is short-term and manufacturer-funded, with no long-term safety data. Confidence: moderate for short-term benefit, low for long-term safety.
Sources examined 12
-
Lower Respiratory Tract Infections Following Respiratory Syncytial Virus Monoclonal Antibody Nirsevimab Immunization Versus Placebo: Analysis From a Phase 3 Randomized Clinical Trial (MELODY)
In a large phase 3 randomized trial (MELODY) of nirsevimab vs placebo in healthy term and late‑preterm infants, nirsevimab reduced RSV-associated medically attended lower respiratory tract infections through day 511 without evidence of replacing RSV with other respiratory viruse…
DOI: 10.1093/cid/ciae596 -
Universal administration of nirsevimab in infants: an analysis of hospitalisations and paediatric intensive care unit admissions for RSV-associated lower respiratory tract infections
This study evaluates the impact of universal nirsevimab administration on hospitalizations and pediatric intensive care unit admissions for RSV-associated lower respiratory tract infections in infants, revealing significant reductions in both metrics, particularly among infants …
DOI: 10.1007/s00431-025-06125-5 -
Nirsevimab Prophylaxis and Respiratory Syncytial Virus Hospitalizations Among Infants
A retrospective multicenter Italian cohort study showing that universal nirsevimab prophylaxis substantially reduces RSV-related hospitalization risk in the first year of life, with residual higher risk for preterm infants and those living with older siblings, and suggesting mil…
DOI: 10.1001/jamanetworkopen.2025.44679 -
RSV-Prophylaxe
Long-acting monoclonal antibody Nirsevimab and maternal vaccine Abrysvo are transforming RSV prophylaxis by enabling less frequent dosing and broader protection, with trial data showing substantial reductions in RSV-LRTI and hospitalization in infants.
DOI: 10.1007/s00608-023-01171-4 -
Respiratory syncytial virus–related lower respiratory tract infection hospitalizations in infants receiving nirsevimab in Galicia (Spain): the NIRSE-GAL study
The NIRSE-GAL study investigates the clinical characteristics and outcomes of respiratory syncytial virus (RSV)-related lower respiratory tract infection hospitalizations in infants receiving nirsevimab in Galicia, revealing that a significant proportion of hospitalized infants …
DOI: 10.1007/s00431-025-06151-3 -
Public health impact of nirsevimab and reduction of RSV hospitalisation in all infants: early real-world data from Tuscany (Italy) in the 2024–25 RSV season
This real-world study from Tuscany, Italy evaluates the public health impact of universal nirsevimab immunization on RSV-related hospitalisations and PICU admissions during the 2024-25 RSV season, showing substantial reductions across birth cohorts and supporting universal vacci…
DOI: 10.1007/s00431-025-06588-6 -
Changes in RSV-associated lower respiratory tract infections among hospitalized and outpatient children under 2 years in Northern Bavaria after general recommendation of Nirsevimab immunization in 2024
Newborn Nirsevimab immunization coverage reached about 68% in Würzburg during 2024/25, and RSV-LRTIs among hospitalized and outpatient infants under 2 declined relative to prior seasons, aligning with national surveillance and suggesting a positive impact of the immunization rol…
DOI: 10.1007/s15010-025-02654-1 -
Summer 2023 ACIP Update: RSV Prevention and Updated Recommendations on Other Vaccines
ACIP's Summer 2023 update outlines RSV prevention advances, notably nirsevimab for infants, and revised pediatric vaccine recommendations across influenza, pneumococcal, meningococcal, mpox, and COVID-19, with emphasis on implementation, safety monitoring, and cost consideration…
DOI: 10.1542/peds.2023-063955 -
How a major discovery can become a public health failure when used subotptimally: lessons from early nirsevimab implementation
Two Italian observational analyses from a Rome university hospital show that partial, late implementation of nirsevimab for RSV prevention yielded negligible impact on RSV bronchiolitis hospitalizations in the first year and incurred substantial costs, arguing for universal cove…
DOI: 10.1186/s13052-025-02147-9 -
Complete definition of how mutations affect antibodies used to prevent RSV
Biophysical modeling of bivalent IgG binding combined with deep mutational scanning maps how almost all RSV F mutations alter neutralization by nirsevimab and other antibodies, explaining subtype differences and enabling real-time resistance surveillance.
DOI: 10.64898/2026.02.12.705519 -
Turkish pediatricians’ knowledge, attitudes, and awareness of respiratory syncytial virus (RSV) infection and immunization strategies: a cross-sectional study
Turkish pediatricians exhibit substantial gaps in RSV vaccine and nirsevimab knowledge, with frequent non-evidence-based practices (e.g., chest X-rays and nebulized therapies) and limited awareness of maternal vaccination, signaling an urgent need for targeted clinician educatio…
DOI: 10.24953/turkjpediatr.2025.5528 -
Use of Clesrovimab for Prevention of Severe Respiratory Syncytial Virus–Associated Lower Respiratory Tract Infections in Infants: Recommendations of the Advisory Committee on Immunization Practices — United States, 2025
ACIP recommends clesrovimab as an alternative to nirsevimab for preventing RSV-associated lower respiratory tract infections in infants under 8 months during their first RSV season, based on a phase 2b/3 randomized trial showing substantial protection against medically attended …
DOI: 10.15585/mmwr.mm7432a3